NASDAQ · HEPA
Healthcare · Biotechnology
$0.08
Down-$0.02 (-15.79%)
Updated Sep 1, 2026, 4:05 AM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
HEPA does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning HEPA.
HEPA research
Company profile and research snapshot.
HEPION PHARMS INC
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 7, 2023 | Brookline Capital | Hold | — |
| Feb 28, 2022 | Cantor Fitzgerald | Overweight | — |
| Nov 22, 2019 | Brookline Capital | Buy | — |
| Mar 20, 2019 | Maxim Group | Hold | — |
| Jul 10, 2018 | Maxim Group | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Dec 11, 2024
Hepion Pharmaceuticals has terminated its merger agreement with Pharma Two B Ltd. and has withdrawn proposals for a special stockholder meeting. The company is continuing efforts to provide value from its drug candidate rencofilstat to shareholders.
GlobeNewswire Inc. · Dec 2, 2024
Hepion Pharmaceuticals is urging shareholders to approve a merger with Pharma Two B, as the company faces challenges in continuing the development of its drug pipeline due to limited financial resources. The merger would allow Hepion's shareholders to participate in the potential upside of Pharma Two B's late-clinical stage Parkinson's disease candidate.
GlobeNewswire Inc. · Apr 19, 2024
EDISON, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today announced that it has begun wind-down activities in its ASCEND-NASH Trial, while continuing to explore strategic alternatives, as previously announced in December 2023.
GlobeNewswire Inc. · Mar 6, 2024
EDISON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, and other chronic diseases, today announced the appointment of Michael Purcell to the Company’s Board of Directors, effective March 5, 2024.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning HEPA.
